Vivek Kumar

Vivek Kumar

Auto-generated profile, based on publicly available information

Vivek Kumar

Department of Pharmacology, Rajiv Academy for Pharmacy, Mathura (U.P.), India, Kashi Institute of Pharmacy, MS 23KM, Varanasi – Prayagraj (Allahabad) Highway, Mirzamurad, Varanasi, Uttar Pradesh, 221307, India

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2023 in Defence Life Science Journal
Verified
Journal Article
Open access
PDF file
VKVivek Kumar
Vivek Kumar
MYMahendra Yadav
Mahendra Yadav
KDKunal Dhankhar
Kunal Dhankhar
DPDharam Pal Pathak
Dharam Pal Pathak
NSNidhi Sandal
Nidhi Sandal
The physicochemical properties of insoluble Prussian blue (PB) play an important role in its thallium binding ability. Therefore, the present study aimed to characterise various physicochemical parameters of PB available commercially and compare them with the USFDA-approved Radiogardase ® -Cs. In addition, PB was synthesised by indirect and direct methods. PB samples and Radiogardase®-Cs were analysed for various parameters like particle size, moisture content, and thermogravimetric analysis (TGA) and correlated with its Maximum Binding Capacity (MBC) for thallium. Radiogardase ® -Cs showed the highest MBC of 238 mg/g for thallium with D 90 of 785 μm and moisture content of 23.24 %. The MBC of other PB samples was found to be significantly lower than Radiogardase ® -Cs which was found to be directly proportional to the moisture content. However, other parameters like particle size, and iron content vary significantly but no correlation was observed with MBC for thallium. This finding suggests that moisture content and MBC are extremely important parameters for optimising the PB to achieve desirable pharmacological efficacy for removing thallium in vivo.

21 May 2026 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
VKVivek Kumar
Vivek Kumar
SKSaurav Kumar
Saurav Kumar
RKRavi Kumar
Ravi Kumar
NTNidhi Tiwari
Nidhi Tiwari
JGJeetendra Kumar Gupta
Jeetendra Kumar Gupta
SignificanceThe review aims to systematically explore the transformative impact of artificial intelligence (AI) on pharmaceutical sciences. It Address key research questions regarding how AI accelerates drug development, enhances clinical trial design, optimizes manufacturing, and drives advances in personalized and precision medicine.MethodsA comprehensive literature review was conducted. It Synthesized recent studies, industry reports, and regulatory guidelines on AI adoption. Covered drug discovery, clinical trials, pharmacovigilance, manufacturing, supply chain management, and pharmacy education. It also critically examined barriers such as data quality, privacy, explainability, and the evolving regulatory landscape.ResultsAI accelerates pharmaceutical R&, identification, lead optimization, ADMET prediction, drug repurposing, and clinical trial analytics. It enables faster and more cost-effective development. Advancements in personalized medicine and individualized patient data are driving better patient outcomes. The students still ace continuing challenges in data interpretation, privacy, and regulatory issues.ConclusionsOngoing AI advancements and evolving regulations are set to revolutionize pharmaceutical science. They will enable efficient, predictive, and patient-centered healthcare. Success will depend on integrating multi-omics, adopting explainable AI, and fostering collaboration among all stakeholders. Ultimately, AI promises safer, faster, and more precise drug delivery system. It benefits clinicians, researchers, and students, and students.

4 September 2026 in Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
TVTushar Varshney
Tushar Varshney
SSSukhdev Sharma
Sukhdev Sharma
VKVibha Kumari
Vibha Kumari
MSManu Sharma
Manu Sharma
VKVivek Kumar
Vivek Kumar
Introduction: Bigel formulations are multifunctional two-phase systems that incorporate hydrogels and organogels in varying ratios, maximizing the functional advantages of the water and oil phases. Such a biphasic system addresses the drawbacks of monophasic gels, in which organogels enhance transdermal penetration while the hydrogel maintains adequate hydration of the stratum corneum. Methods: A hydrogel system was dispensed by gradually adding Carbopol 940 into distilled water while maintaining uniform stirring. For the preparation of organogels, Span 20 and Span 80 were incorporated into olive oil at an elevated temperature (60°C) with constant agitation. The final hydrogel and organogel bases were homogenized in varying proportions to obtain bigel formulations. The formulation was evaluated for parameters such as spreadability, extrudability, swelling behaviour, drug content, in vitro drug release profile, stability testing, and antimicrobial assessment. results: Among all batches, formulation B5 exhibited the highest drug release (80.81% at 6 hours) and demonstrated potent antimicrobial efficacy, as reflected by a zone of inhibition ranging from 17.43 ± 0.04 mm to 36.33 ± 1.15 mm against microbial strains. Result: The formulations were comprehensively evaluated for physicochemical characteristics such as spreadability, extrudability, swelling behaviour, viscosity, drug content, and stability upon centrifugation. Among the prepared batches, B5 showed the highest drug release (94.1% at 8 h) and displayed significant antimicrobial activity, producing zones of inhibition ranging from 17.43 ± 0.04 mm to 36.33 ± 1.15 mm against the tested microbial strains. Stability studies demonstrated their physicochemical properties throughout the three-month accelerated stability study, indicating robustness. Discussion: Effective topical administration against Candida albicans was demonstrated by the optimal release, stability, and antifungal activity of B5 optimized clotrimazole bigel. With all factors considered, outcomes suggest bigel-based administration as a feasible approach for enhancing local clotrimazole therapy while retaining high patient acceptability. Conclusion: Among the prepared batches, B5 showed the largest zone of inhibition (36.33 ± 1.15 mm) against Candida albicans, demonstrating the potential of the developed bigel as an effective topical treatment for cutaneous fungal infections.